POWERFUL PROPHYLAXIS
FAST AND SUSTAINED
PROTECTION YOU
CAN RELY ON
Photo does not depict actual patient
Image
Attack reduction has been maintained throughout ongoing clinical trials*
* 2+ years and counting.
Image
Image
ANDEMBRY, THE FIRST AND ONLY ONCE-MONTHLY HAE PROPHYLAXIS TREATMENT FROM THE START FOR ALL PATIENTS
- Monthly dosing from the start for all patients 12 years and older
- Subcutaneous self-injection delivered in ≤15 seconds via a convenient autoinjector
- No reports of injection-site pain§
§ In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway